top of page

There's an Elephant in the Room. It's Really Skinny.

There's a concerning rise of GLP-1 usage among college-aged students


Image credit: Jasper Langley-Hawthorne
Image credit: Jasper Langley-Hawthorne

One of the college-aged, non-obese authors of this article got approved for GLP-1s online in around five minutes.


He took a handful of clicks on an animated, green and gray survey that included as many pop-ups about first-time discounts as it did clinically relevant evaluations. The obvious marketing campaign and ease of approval was surprising, but we’ve all heard the off-hand Ozempic comments and seen the ads. These drugs are everywhere.


While seemingly harmless, the rise in GLP-1s reflects a deeper issue within college culture: the normalization and medical treatment of body dissatisfaction. You only need to drop into Roberts Pavilion or Pomona’s CARW, where you’ll occasionally hear “I’m fat as f*ck” or “Maybe I need to hop on the ‘O.’” Nationally, between 2020 and 2023, researchers at the University of Michigan found a 481 percent increase in GLP-1 usage among males and a 660 percent increase among females, aged 18 to 25.


For some, these insecurities can become debilitating. Body dysmorphic disorder (BDD) affects an estimated three percent of students in higher education. Yet, even among students who do not meet the clinical criteria for BDD, dissatisfaction with one's appearance can develop unhealthy relationships with food, exercise, and weight management. In a social environment where being lean is often equated with being healthy, attractive, or disciplined, the pressure to achieve an idealized body can be difficult to escape.


This pressure becomes particularly concerning with the growing popularity and relative ease of weight-loss medications, specifically GLP-1s, or glucagon-like peptide-1 receptor agonists. Commonly recognized through brand names such as Ozempic and Wegovy, these medications have become increasingly prominent in conversations about weight loss. Originally developed to treat type 2 diabetes, certain GLP-1 medications are now commonly prescribed for chronic weight management in individuals with obesity.


The author's quick approval for GLP-1 use, featuring a first-time "intro offer."  |  Image credit: Cooper Lahti
The author's quick approval for GLP-1 use, featuring a first-time "intro offer." | Image credit: Cooper Lahti

GLP-1 drugs work by mimicking the naturally occurring GLP-1 hormone which is released by the gut in response to food consumption. These drugs induce the same downstream effects as our natural hormones, namely increased satiety and decreased food craving. They are more effective for weight loss in obese patients than any medication previously produced. Furthermore, research has shown demonstrated benefits for patients with certain cardiovascular and metabolic conditions, with ongoing investigations into additional therapeutic applications.


For individuals with legitimate medical needs, GLP-1 medications represent a significant advancement in modern medicine. As GLP-1 medications become more visible in popular culture, however, they appear to offer a convenient solution to the very body image insecurities that many college students struggle with. The same University of Michigan researchers suggest that the sharp increases in GLP-1 usage stem from “off-label” prescription for patients who aren’t obese. 


Although GLP-1 medications have important therapeutic applications, we argue that they should not be used by otherwise healthy college students hoping to conform to societal beauty standards. The question is not simply whether these medications can help students lose weight, but whether losing weight is something they medically need.


For one, there are the myriad unintended effects and unknown risks of GLP-1s.

Gastrointestinal side effects including nausea, diarrhea, vomiting, and constipation occurred in 74.2 percent of the patient population taking semaglutide, or the name brand Wegovy and Ozempic, compared to 47.9 percent on placebo. Rarer, more serious risks include gallbladder disease and pancreatitis, and Wegovy in particular carries a boxed warning for thyroid tumors seen in rodent studies. 


In addition, weight loss isn’t all about fat. In a DEXA body composition substudy of the same semaglutide trial, total lean body mass fell by 9.7 percent, which introduces new potential health concerns such as decreased strength and mobility, slower metabolism, and higher risk of bone fractures. 


Then there’s the price. Wegovy lists at roughly $1,349 a month, and even discounted cash options still run between $149 and $399 a month through the manufacturer’s pharmacy. That puts a lot of strain on a college budget, and tempts people toward cheaper, less regulated sources that have higher potential to cause adverse events. It also further divides accessibility based on socioeconomic opportunity.


It's important to remember, however, that GLP-1s such as Ozempic and Wegovy are popular because they work. For each five-point increase in Body Mass Index (BMI) there is a 30 percent increase in all-cause mortality, so a drop in weight for obese patients means a drop in risk. Wegovy, for example, dropped weight by 15 to 17 percent in just 68 weeks — that’s 5.0 BMI points for someone right at the obese cutoff. This means that in a little over a year, from a pill or injection alone, a patient can make a significant dent in their all-cause mortality.


The older gentleman next door who has been struggling with his weight for decades and is beginning to see the destructive power of heart disease and stroke in his loved ones now, more than ever, has a solution. A GLP-1 could be the difference between being around for your grandkids or not — health or sickness, life or death. But we’ve seen that GLP-1s are very far from a silver bullet. The question then becomes: At what point do the benefits outweigh the risks? Who is the ideal patient for Ozempic and Wegovy? 


Wegovy’s adult indication requires a BMI of at least 30, or 27 with a weight-related condition, so the non-obese student has little medical benefit to weigh against the risks. What these drugs may bring instead are high levels of body dissatisfaction and an increased vulnerability to “easy fix” medications. In one study, 32.1 percent of patients with eating disorders had used a GLP-1, and about 10 percent had misused one.


For someone sensitive about their perceived flaws, a lower number on the scale may not quiet the insecurity, and the results may not last: Semaglutide trial participants regained two-thirds of their lost weight within a year after quitting. That leaves a choice between indefinite treatment and a rebound, all in response to a pressure that, for many, is not a medical problem.


So keep GLP-1s on the shelves, as many Americans need them. But if you’re a non-obese student without a medical condition, please, be wary of the pressures and risks. Our older gentleman next door is evaluating a real threat against real risks. A healthy-weight student muttering “I need to get leaner” in Roberts is not. 

 
 

The Forum is the Claremont Colleges’ open-submission paper featuring thoughtful and incisive commentary.

  • Instagram
The Forum Logo (the thinker)

Sponsored by Claremont McKenna's Salvatori Center for the Study of Individual Freedom

Unless otherwise noted, pieces reflect the opinions of the authors and not the opinions of The Forum or the Salvatori Center

bottom of page